Active

Developing natural nanoparticle “smart bombs” to target hard-to-treat tumours

Cancer types:

General cancer research
Breast cancer

Project period:

Research institute:

Universita Degli Studi di Genova

Award amount:

£170,000

Location:

Italy

Roberta Tasso Headshot
Researcher Professor Roberta Tasso

Professor Roberta Tasso and her team have an ambitious plan: to find new ways to deliver drugs straight to hard-to-treat tumours. By using nanoparticles that occur naturally in our bodies as “smart bombs”, the team hope to be able to knock out tumours even after cancer has spread.

Hope for the future

Metastasis – the process in which cancer spreads from the original tumour to other parts of the body – is the leading cause of cancer death. A combination of surgery, chemotherapy and radiotherapy can usually treat cancer if it is caught early, but once the disease has spread it can become incurable. Developing better ways of preventing and treating metastasis is crucial in stopping lives being cut short by cancer.


With Curestarter support, Professor Tasso and her team are investigating new ways of diagnosing metastasis and delivering chemotherapy drugs specifically to metastatic tumours. This means targeting the cancerous cells, while surrounding healthy cells are not affected. Research like this is the first step in developing new cures for late stage cancer patients, giving them a chance at recovery.

Meet the scientist

Professor Roberta Tasso is a passionate researcher, spending most of her days in the laboratory with her team. Nevertheless she loves spending her free time going to the theater and concerts. She’s a huge music enthusiast, particularly rock music. She also enjoys spending time with her friends – especially indulging in sushi!

The science

Artificially-created nanoparticles are already used in cancer therapies to deliver drugs around the body, but don’t always work as well as expected. Professor Tasso and her team are exploring an innovative approach using a nanoparticle called an extracellular vesicle, or EV, to deliver drugs straight to metastatic tumours. These tiny, fat-covered particles are produced naturally by our cells, and can carry information around our bodies.


The team expects EV nanoparticles to be much more efficient in targeting metastatic cancer cells and avoiding healthy tissue, which could lead to new ways to detect metastasis as well as a kinder treatment with fewer side effects. One way EVs do this is by attaching onto the unique tissue that grows around a tumour, rather than the tumour itself. As they are a familiar particle that already occur in our bodies, they are easily absorbed and travel freely through the bloodstream into hard-to-reach organs.


The team will engineer these EVs to hold known effective anti-cancer drugs, which are protected by the fatty layer around the particles which means they can elude our immune system. They will test this on breast cancer tumours using Paclitaxel, a widely-used chemotherapy drug.

If effective, this novel drug delivery system could be used with different drugs to treat other metastatic cancers. They hope that their exciting research will show that this method of targeting tumours is not only more effective than existing therapies, but is also cheaper and gentler for patients.

Our research is fueled by a fundamental vision: a world where cancer no longer cuts lives short prematurely.

Roberta Tasso Headshot
Professor Roberta Tasso

Related projects

Andres Hidalgo Headshot

Active Spain

Lung cancer

How do cancer cells modify white blood cells to help tumours grow?

Researchers want to help immunotherapy work for more cancer patients by understanding how cancers hijack our immune system and preventing this happening 

Researcher: Dr Andrés Hidalgo

Understanding how cancer cells modify white blood cells to help tumours grow
Andrew Beekman and Team

Active United Kingdom

General cancer research

Can we stop cancer becoming resistant to chemotherapy?

Chemotherapy can sometimes stop working, so this project is hoping to better understand why and find ways to give more, better options to cancer patients.

Researcher: Dr Andrew Beekman

Stopping cancer becoming resistant to chemotherapy
Tim Elliott and Team

Active United Kingdom

General cancer research

Can we predict which patients will respond to immunotherapy?

This project hopes to open up exciting possibilities for personalised cancer treatment by finding how to predict which patients will respond best to treatment.

Researcher: Professor Tim Elliott

Finding ways to predict which patients will respond to immunotherapy
Share this page